Hoenlein Malcolm 4
4 · Fortress Biotech, Inc. · Filed Apr 29, 2022
Insider Transaction Report
Form 4
Hoenlein Malcolm
Director
Transactions
- Other
Common Stock
2021-09-30+406→ 435,406 total - Award
Common Stock
2022-01-01+50,000→ 485,636 total - Other
Common Stock
2021-11-16+230→ 435,636 total
Footnotes (5)
- [F1]The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock.
- [F2]The total holdings include 350,000 shares underlying deferred restricted stock units.
- [F3]The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock
- [F4]One-third of the shares will vest on each of January 1, 2023, 2024, and 2025, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
- [F5]The total holdings include 400,000 shares underlying deferred restricted stock units.